We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Sectra Extends Medical Diagnostics Business to Include Genomics IT

By LabMedica International staff writers
Posted on 02 Sep 2022
Print article
Image: Sectra\'s enterprise diagnostic IT platform will be extended to efficiently handle genomics information (Photo courtesy of Sectra)
Image: Sectra\'s enterprise diagnostic IT platform will be extended to efficiently handle genomics information (Photo courtesy of Sectra)

Analysis of genetic information, genomics, is used in healthcare today to better understand and diagnose patients and to predict how an individual patient may react to different treatments. Individualized care based on genetic information is often referred to as precision medicine and is a rapidly growing field. To leverage the possibilities of precision medicine and to cope with a dramatic increase in the volume of patient data, tomorrow's IT solutions for diagnostics need to provide healthcare providers with information across multiple specialties, including genomics, along with support for integrated diagnostic workflows.

Sectra (Linköping, Sweden), an international medical imaging IT and cybersecurity company, and the University of Pennsylvania Health System (Philadelphia, PA, USA), have initiated a collaboration to facilitate the development of an effective IT solution. Sectra is initiating a new business unit to drive innovation and product development within the area of genomics. In the future, Sectra's enterprise diagnostic IT platform will be extended to efficiently handle genomics information - a further step in Sectra's drive towards integrated diagnostics. This multidisciplinary approach is particularly important in cancer care.

The new business unit is part of Sectra's operating area Business Innovation. The IT solution for genomic information will be part of Sectra's enterprise imaging solution, which provides a unified strategy for all imaging needs while lowering operational costs. The scalable and modular solution, with a VNA at its core, allows healthcare providers to grow from ology to ology and from enterprise to enterprise.

"Genetic information is becoming increasingly important in diagnostics and precision medicine, especially within cancer care. Investing in genomics fits perfectly with our long-term ambition to be the leader in diagnostics information technology and has the potential to significantly impact patient care," says Torbjörn Kronander, President and CEO of Sectra.

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.